By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Depomed, Inc. 

7999 Gateway Boulevard
Suite 300
Newark  California  94560  U.S.A.
Phone: 510-744-8000 Fax: 510-744-8001


Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients.

Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. The company’s Acuform technology is currently being used in four marketed drugs, including Gralise.

The Company has successfully executed on strategy and has grown product revenue significantly over the past three years. Located in Newark, CA, Depomed is NASDAQ-listed (DEPO) and currently employs approximately 325 people, of which approximately 250 are within the Commercial organization.

On January 15, 2015, Depomed announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. NUCYNTA (tapentadol) oral solution is an approved oral form of tapentadol that has not been launched. The deal will make NUCYNTA the flagship asset in Depomed's growing portfolio of pain and neurology specialty pharmaceuticals, and is expected to close in 2Q15.

Key Statistics

Ownership: Public

Web Site: Depomed
Symbol: DEPO


Drug Delivery

Company News
Activist Investor Starboard Calls for Meeting to Overhaul Depomed (DEPO)'s Board 5/26/2016 8:46:16 AM
10 Biotech Stocks Analysts are Upbeat About in May 5/23/2016 8:24:58 AM
Simmering Power Struggle Between Depomed (DEPO) and Hedge Fund Starboard Value Comes to a Boil 4/15/2016 5:53:29 AM
Depomed (DEPO) Issues Statement In Response To Starboard Value LP 13D Filing 4/8/2016 11:11:58 AM
Depomed (DEPO) Investor Seeks to Replace Six Board Members After Taking Stake in Drugmaker 4/8/2016 5:59:46 AM
Depomed (DEPO) To Report Fourth Quarter Fiscal Year 2015 Financial Results On Monday, February 22, 2016 2/16/2016 11:00:39 AM
Three Underperforming Biopharma Companies Worth Looking At 2/15/2016 6:24:02 AM
After Dropping Depomed (DEPO), Horizon Pharma (HZNP) Forks Over $510 Million Cash for Crealta Holdings 12/11/2015 5:50:15 AM
Depomed (DEPO) To Present At Four Investor Events In December 11/24/2015 7:34:09 AM
Horizon Biopharm Pulls Out of $2 Billion Hostile Takeover Bid for Depomed (DEPO) After Court Ruling 11/20/2015 5:49:11 AM